Services-Commercial Physical & Biological Research
Standard Industrial Classification: SIC 8731
Industry Insider Sentiment Analysis
The Services-Commercial Physical & Biological Research sector (SIC 8731) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-15 23:02 | 2023-05-12 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Director, Officer | BUY | $3.40 | 440,000 | $1,496,000 | 2,438,414 |
| 2023-05-15 21:49 | 2023-05-12 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | LaPlume Joseph W | Officer | SELL | $193.03 | 959 | $185,116 | 24,371 |
| 2023-05-15 21:42 | 2023-05-11 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | MASSARO GEORGE | Director | SELL | $193.43 | 288 | $55,708 | 4,964 |
| 2023-05-06 00:09 | 2023-05-03 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.02 | 16,149 | $81,068 | 333,197 |
| 2023-04-27 23:24 | 2023-04-25 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Director, Officer, 10% owner | SELL | $221.83 | 31,648 | $7,020,476 | 6,451,371 |
| 2023-04-27 23:23 | 2023-04-25 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% owner | SELL | $221.83 | 31,648 | $7,020,476 | 6,451,371 |
| 2023-04-26 00:33 | 2023-04-21 | NRC | NATIONAL RESEARCH CORP | Amandla MK Trust | 10% owner | SELL | $45.03 | 1,300 | $58,537 | 4,403,934 |
| 2023-04-13 00:03 | 2023-04-10 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.00 | 14,134 | $70,670 | 0 |
| 2023-04-12 23:37 | 2023-04-10 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.00 | 15,000 | $75,000 | 333,197 |
| 2023-04-07 23:43 | 2023-04-05 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.02 | 34,160 | $171,616 | 0 |
| 2023-04-07 23:42 | 2023-04-05 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.02 | 34,823 | $174,951 | 333,197 |
| 2023-04-05 02:00 | 2023-03-31 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.02 | 9,973 | $50,084 | 0 |
| 2023-04-05 01:59 | 2023-03-31 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.02 | 10,177 | $51,110 | 333,197 |
| 2023-04-05 00:49 | 2023-03-31 | NRC | NATIONAL RESEARCH CORP | RAASCH JONA S | Officer | SELL | $43.61 | 23,931 | $1,043,511 | 1,688 |
| 2023-03-31 23:17 | 2023-03-29 | NRC | NATIONAL RESEARCH CORP | RAASCH JONA S | Officer | SELL | $43.49 | 25,000 | $1,087,263 | 25,619 |
| 2023-03-30 16:11 | 2023-03-29 | MXCT | MAXCYTE, INC. | DOUGLAS RICHARD | Director | BUY | $4.32 | 80,000 | $345,480 | 100,000 |
| 2023-03-16 23:03 | 2023-03-14 | NOTV | Inotiv, Inc. | Sagartz John E | Director, Officer | BUY | $4.91 | 5,100 | $25,041 | 692,047 |
| 2023-03-01 01:16 | 2023-02-24 | NRC | NATIONAL RESEARCH CORP | Karas Kevin R | Officer | SELL | $45.68 | 11,912 | $544,096 | 5,384 |
| 2023-02-25 00:02 | 2023-02-22 | NOTV | Inotiv, Inc. | Beattie John Gregory | Officer | BUY | $6.99 | 5,000 | $34,950 | 63,795 |
| 2023-02-25 00:20 | 2023-02-23 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | WALLMAN RICHARD F | Director | BUY | $220.73 | 1,750 | $386,278 | 21,864 |
| 2023-02-22 00:11 | 2023-02-16 | NRC | NATIONAL RESEARCH CORP | Amandla MK Trust | 10% owner | SELL | $47.03 | 6,205 | $291,838 | 4,405,234 |
| 2023-02-22 01:39 | 2023-02-16 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Parisotto Shannon M | Officer | OPT+S | $254.41 | 4,558 | $1,159,619 | 6,010 |
| 2023-02-18 01:13 | 2023-02-16 | IQV | IQVIA HOLDINGS INC. | Knightly Kevin C | Officer | SELL | $225.61 | 4,446 | $1,003,068 | 1,973 |
| 2023-02-18 01:29 | 2023-02-16 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Girshick Birgit | Officer | OPT+S | $254.39 | 3,205 | $815,310 | 41,038 |
| 2023-02-18 00:02 | 2023-02-15 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | FOSTER JAMES C | Director, Officer | SELL | $250.00 | 20,000 | $5,000,018 | 216,594 |
| 2023-02-16 01:58 | 2023-02-14 | IQV | IQVIA HOLDINGS INC. | Sherbet Eric | Officer | SELL | $230.00 | 1,000 | $230,000 | 17,053 |
| 2023-02-10 00:34 | 2023-02-07 | NRC | NATIONAL RESEARCH CORP | Amandla MK Trust | 10% owner | SELL | $47.03 | 100 | $4,703 | 4,411,439 |
| 2023-02-07 00:33 | 2023-02-02 | NRC | NATIONAL RESEARCH CORP | Amandla MK Trust | 10% owner | SELL | $47.34 | 100 | $4,734 | 4,411,539 |
| 2023-02-04 00:32 | 2023-02-01 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.72 | 29,133 | $166,518 | 0 |
| 2023-02-04 00:31 | 2023-02-01 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.72 | 30,000 | $171,552 | 333,197 |
| 2023-02-03 00:00 | 2023-01-31 | INCY | INCYTE CORP | Pasquale Maria E | Officer | OPT+S | $84.06 | 802 | $67,416 | 68,524 |
| 2023-02-02 00:00 | 2023-01-30 | INCY | INCYTE CORP | Pasquale Maria E | Officer | OPT+S | $84.74 | 60,024 | $5,086,572 | 68,524 |
| 2023-01-31 00:00 | 2023-01-26 | INCY | INCYTE CORP | Dhanak Dashyant | Officer | SELL | $85.00 | 2,419 | $205,615 | 53,263 |
| 2023-01-31 00:00 | 2023-01-26 | INCY | INCYTE CORP | Iyengar Vijay K | Officer | OPT+S | $85.00 | 7,000 | $595,000 | 42,835 |
| 2023-01-13 19:24 | 2023-01-12 | DKDCA | OneMedNet Corp | Shaolin Capital Management LLC | 10% owner | SELL | $10.48 | 100,000 | $1,048,000 | 400,000 |
| 2023-01-12 01:33 | 2023-01-09 | NRC | NATIONAL RESEARCH CORP | Amandla MK Trust | 10% owner | SELL | $40.72 | 6,370 | $259,387 | 4,411,639 |
| 2023-01-07 00:00 | 2023-01-04 | INCY | INCYTE CORP | Stein Steven H | Officer | SELL | $79.78 | 28,399 | $2,265,672 | 109,021 |
| 2023-01-06 01:39 | 2023-01-03 | MXCT | MAXCYTE, INC. | Doerfler Douglas | Director, Officer | OPT+S | $5.08 | 30,000 | $152,430 | 333,197 |
| 2023-01-06 01:31 | 2023-01-03 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.08 | 29,133 | $148,051 | 0 |
| 2022-12-29 15:12 | 2022-12-09 | NOTV | Inotiv, Inc. | Pitchford William D | Officer | SELL | $5.82 | 2,123 | $12,366 | 74,051 |
| 2022-12-29 00:00 | 2022-12-23 | INCY | INCYTE CORP | Iyengar Vijay K | Officer | OPT+S | $80.80 | 17,324 | $1,399,739 | 37,855 |
| 2022-12-22 00:00 | 2022-12-19 | INCY | INCYTE CORP | Tray Thomas | Officer | SELL | $82.16 | 1,223 | $100,482 | 16,606 |
| 2022-12-15 01:00 | 2022-12-12 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Director, Officer | BUY | $3.77 | 150,000 | $564,765 | 1,838,084 |
| 2022-12-09 01:57 | 2022-12-06 | OABI | OmniAb, Inc. | Cochran Jennifer R. | Director | BUY | $3.75 | 22,250 | $83,527 | 77,476 |
| 2022-12-07 01:31 | 2022-12-02 | MXCT | MAXCYTE, INC. | Ross Thomas M. | Officer | OPT+S | $5.81 | 29,133 | $169,304 | 0 |
| 2022-12-07 00:12 | 2022-12-02 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | WALLMAN RICHARD F | Director | BUY | $218.90 | 1,500 | $328,350 | 20,114 |
| 2022-12-07 00:40 | 2022-12-02 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Barbo William D | Officer | OPT+S | $219.91 | 3,205 | $704,814 | 3,803 |
| 2022-12-06 00:12 | 2022-08-31 | BIAF | bioAffinity Technologies, Inc. | KNIGHT PETER S | Director | BUY | $0.00 | 8,163 | $0 | 22,448 |
| 2022-12-06 00:55 | 2022-12-01 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | LaPlume Joseph W | Officer | OPT+S | $224.25 | 6,409 | $1,437,205 | 20,232 |
| 2022-12-03 05:31 | 2022-08-31 | BIAF | bioAffinity Technologies, Inc. | Anderson Robert A. | Director | BUY | $0.00 | 4,081 | $0 | 4,081 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Services-Commercial Physical & Biological Research sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (8731) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Services-Commercial Physical & Biological Research
Every transaction in the Services-Commercial Physical & Biological Research industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.